Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [0.03%]
沙格列汀——一种治疗二型糖尿病的二肽基肽酶Ⅳ抑制剂
Baptist Gallwitz
Baptist Gallwitz
Saxagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, is currently under development by Bristol-Myers Squibb Co, AstraZeneca plc and Otsuka Pharmaceutical Co Ltd for the treatment of type 2 diabetes. The compound has high selectivity f...
Prediction of CYP-mediated drug interactions in vivo using in vitro data [0.03%]
基于体外数据预测由细胞色素P450介导的药物相互作用的体内模型
Robert S Foti,Jan L Wahlstrom
Robert S Foti
Over the past 15 years, a concerted effort has been undertaken by the pharmaceutical industry to reduce the attrition of clinical candidates resulting from undesirable ADME characteristics. Increasing regulatory and competitive pressures de...
Arthur M Doweyko
Arthur M Doweyko
The concept of quantitative SAR (QSAR) is inherently imbued with an expectation of predictivity, novel insights and the generation of useful hypotheses, particularly as applied to the drug discovery process. However, even recently developed...
bioLOGIC Europe 2008 [0.03%]
2008生物逻辑欧洲大会
Claire Veryard
Claire Veryard
Divina Glah,Jonathan Bright
Divina Glah
Saloni Shah
Saloni Shah
Frédéric Denonne
Frédéric Denonne